| Hypoglycemic Coma in a Patient with Metastatic Renal Cell Carcinoma Treated with Sunitinib |
|
Meyoung Cho1, Hyeok Shim2, Moo-Rim Park2 |
1Department of Internal Medicine, Gunsan Medical Center, Gunsan, Korea
2Department of Internal Medicine, Wonkwang University School of Medicine, Iksan, Korea |
| Sunitinib 치료 중인 전이성 신세포암 환자에서 발생한 저혈당성 혼수 |
|
조미영1, 심혁2, 박무림2 |
1군산의료원 내과
2원광대학교 의과대학 내과학교실 |
Correspondence:
Hyeok Shim, Tel: +82-63-859-2642, Fax: +82-63-855-202, Email: mdshim@wku.ac.kr
|
|
Received: 27 January 2014 • Revised: 10 March 2014 • Accepted: 28 March 2014 |
|
|
| This is an Open Access article distributed under the terms of the Creative Commons Attribution NonCommercial License (http://creativecommons.org/licenses/bync/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
|
| Abstract |
|
We present a patient with type 2 diabetes mellitus and metastatic renal cell carcinoma who developed severe hypoglycemia and metabolic encephalopathy after sunitinib treatment. Sunitinib, a multi-target tyrosine kinase inhibitor, is used to treat metastatic renal cell carcinoma. Sunitinib-induced hypoglycemia has been reported and there are rare case reports of severe hypoglycemia due to sunitinib. Therefore, glycemic control should be monitored closely in diabetic patients treated with sunitinib. |
| Key Words:
Sunitinib; Hypoglycemia; Metabolic encephalopathy |
| 주제어:
Sunitinib; 저혈당; 대사성 뇌병증 |
PDF Links
Full text via DOI
Download Citation
